# SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC

> **NCT07198165** · PHASE2 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 104 (estimated)

## Conditions studied

- Rectal Cancer
- Rectal Adenocarcinoma
- Rectal Cancer, Radiotherapy
- Rectal Cancer Patients
- Immunotherapy
- Total Neoadjuvant Therapy
- Total Neoadjuvant Treatment
- Targeted Therapy
- Chemoradiotherapy

## Interventions

- **DRUG:** PD-1 inhibitor based immunotherapy

## Key facts

- **NCT ID:** NCT07198165
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-05
- **Primary completion:** 2030-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07198165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07198165, "SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07198165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*